Every 10-Q that Kalaris Therapeutics, Inc. (KLRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KLRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRS filings page.
Kalaris Therapeutics, Inc., a clinical-stage biotech focused on retinal diseases, reported continued losses as it advances lead anti-VEGF candidate TH103. For the quarter ended June 30, 2026, net loss was $11.5 million, and for the first half of 2026, net loss was $22.4 million, with no product revenue.
Quarterly operating expenses were $12.4 million, mainly research and development. Cash, cash equivalents and marketable securities totaled $93.5 million as of June 30, 2026, and management states this should fund operations for at least twelve months from the financial statement issuance date. Cash used in operations for the first half was $22.6 million.
The company carries a related-party royalty obligation of $32.1 million tied to UCSD-licensed technology and remains controlled by majority stockholder Samsara BioCapital. A prior reverse recapitalization with AlloVir reshaped the capital structure, and a $50.0 million private placement plus a $350.0 million shelf and $100.0 million at-the-market facility provide additional capital access. Material weaknesses in internal control over financial reporting are disclosed among key risks.
Kalaris Therapeutics reported a net loss of $10.9 million for the quarter ended March 31, 2026, slightly wider than the $10.2 million loss a year earlier. Operating expenses rose to $11.8 million, driven mainly by higher research and development spending of $7.6 million as the company advances its lead retinal drug candidate TH103.
General and administrative costs were stable at $4.3 million. Other income of $1.0 million partially offset the operating loss. Kalaris ended the quarter with $104.9 million in cash, cash equivalents and marketable securities and total assets of $109.8 million, against total liabilities of $41.2 million, including a $32.1 million royalty obligation to its majority stockholder Samsara BioCapital.
Net cash used in operating activities was $11.6 million, and the company shifted $70.4 million into U.S. Treasury marketable securities. Management believes existing liquidity will fund operating and capital needs for at least 12 months from the financial statement issuance date while it continues developing TH103 for retinal diseases.
Kalaris Therapeutics (KLRS) filed its Q3 2025 10‑Q, reporting a net loss of $11.9 million for the quarter on total operating expenses of $12.7 million (research and development $9.1 million; general and administrative $3.6 million). Year to date, the net loss was $33.4 million.
As of September 30, 2025, cash, cash equivalents and short‑term investments were $77.0 million, and management states these resources are expected to fund operations for at least twelve months. The balance sheet showed total assets of $81.2 million and stockholders’ equity of $41.9 million. A royalty obligation to a related party of $32.1 million remains on the balance sheet.
Kalaris completed a reverse recapitalization with AlloVir on March 18, 2025, bringing $102.1 million of cash and resulting in 18,702,418 shares outstanding post‑merger. The company focuses on TH103, a clinical‑stage anti‑VEGF candidate for retinal diseases. Quarterly loss per share was $0.64.
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on TH103, an anti-VEGF candidate for retinal disease. The company completed its Merger with AlloVir on March 18, 2025; Legacy Kalaris was treated as the accounting acquirer and AlloVir’s cash contribution was recorded as assets acquired.
As of June 30, 2025, Kalaris reported $88.4 million of cash and cash equivalents and stated that existing cash is expected to fund operations for at least twelve months. For the six months ended June 30, 2025, the company recorded a 21.5 million net loss versus $9.1 million in the prior-year period and had an accumulated deficit of $138.1 million. Material items include a $32.076 million royalty obligation to a related party (Samsara), recognition of merger-related transaction costs of $5.4 million reducing additional paid-in capital, and the elimination of outstanding convertible promissory notes, derivative liabilities and the tranche liability in connection with the Merger. The company discloses identified material weaknesses in internal control, dependence on TH103 for future success, and the need to raise additional financing to continue development.